Evidence map›Paper›PMID 34381939›Full record

ArticleBJR open2021

Novel pulmonary vascular imaging signs in COVID-19: pathophysiology, significance and management.

Arshed Hussain Parry, Abdul Haseeb Wani

Abstract read
In one paragraph

Article in BJR open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Arshed Hussain ParryDepartment of Radiodiagnosis, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir, India.
Abdul Haseeb WaniDepartment of Radiodiagnosis, Government Medical College, Srinagar, Jammu & Kashmir, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing body of evidence points to the frequent involvement of pulmonary microvessels in COVID-19 which was recognized first on CT, and subsequently demonstrated by clinical and pathological studies. Microvasculopathy occurring chiefly from endothelial and pericyte damage with resultant disruption of immune, thrombotic and renin-angiotensin-aldosterone balance leads to a constellation of clinical and biochemical derangements. Exploration of potential therapies directed at normalizing the vascular health can prove a major boon in the treatment of COVID-19.

Identifiers

PMID34381939
PMCPMC8320153

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.